archive-fr.com » FR » C » CNG.FR

Total: 170

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CNG - Programmes
    GENOMIC BANK INFRAQTL MADO Autres programmes franco japonaise franco croate PHENOGENE GEN2PHEN Genotype to phenotype databases A holistic solution Coordinator Contact Person SINGER Marie Ms Tel 44 1162231799 Fax 44 1162522028 Email Contact Organisation University of Leicester University Road LEICESTER UNITED KINGDOM Web site http www gen2phen org Project description The EU is contributing 12 million to the GEN2PHEN initative involving the CNG and 16 other partners come from across Europe as well as India and South Africa The GEN2PHEN project will oversee the collection and use of data from research from around the world investigating the links between genetic variation and health The project partners will develop database components tools and technologies that will ensure that all relevant research results can be properly integrated and made available via an online portal called the GEN2PHEN Knowledge Centre Powerful search capabilities will permit researchers and doctors to access and make use of the very latest research in their field In addition to this the project will identify current needs and practices in the genotype phenotype field The ethical aspects relating to the data will also be investigated Participants HELSINGIN YLIOPISTO FINLAND PHENOSYSTEMS SA BELGIUM BIOCOMPUTING PLATFORMS LTD OY FINLAND COUNCIL OF

    Original URL path: http://www.cng.fr/fr/projects/fp7_gen2phen.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    genetic variation in health and disease Coordinator Contact Person BERTERO Michela Tel 34 933160257 Fax 34 9339699832 Email Contact Organisation FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA Doctor Aiguader BARCELONA SPAIN Web site http www geuvadis org Project description High throughput next generation DNA sequencing technologies allow investigators to sequence entire human genomes at an affordable price and within a short time frame The correct interpretation storage and dissemination of the large amount of produced genomics data generate major challenges Tackling these challenges requires extensive exchange of data information and knowledge between medical scientists sequencing centres bioinformatics networks and industry at the European level The GEUVADIS genetic European variation in disease Consortium aims at developing standards in quality control and assessment of sequence data models for data storage exchange and access as well as standards for the handling analysis and interpretation of sequencing data and other functional genomics datasets standards for the biological and medical interpretation of sequence data and in particular rare variants for monogenic and common disorders and finally standards for the ethics of phenotype prediction from sequence variation The partners are all involved in international sequencing initiatives 1000 GP ICGC EU and other international projects ENGAGE GEN2PHEN ENCODE TECHGENE bio banking activities BBMRI data sharing initiatives ELIXIR and the European Sequencing and Genotyping Infrastructure ESGI ensuring tight collaborations The Consortium will undertake pilot sequencing projects on selected samples from three medical fields cardiovascular neurological and metabolic using RNA RNASeq and DNA exonSeq sequencing The analysis of such samples will allow the consortium to set up standards in operating procedures and biological medical interpretation of sequence data in relation to clinical phenotypes The consortium will bring together the knowledge and resources on medical genome sequencing at a European level and allow researchers to develop and test new hypotheses on

    Original URL path: http://www.cng.fr/fr/projects/fp7_geuvadis.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    model system Coordinator Contact Person LEQUARRÉ Anne Sophie Dr Tel 32 26733881 Fax 32 43664116 Email Contact Organisation UNIVERSITE DE LIEGE Place du 20 aout 7 4000 LIEGE BELGIUM Web site http www eurolupa org Project description Despite major efforts identifying susceptibility genes for common human diseases cancers cardiovascular inflammatory and neurological disorders is difficult due to the complexity of the underlying causes The dog population is composed of approximately 400 purebred breeds each one is a genetic isolate with unique characteristics resulting from selection for desired attributes or from inbreeding Dogs tend to suffer from the same range of diseases than human but the genetic complexity of these diseases within a breed is reduced as a consequence of the inbreeding and due to long range linkage disequilibrium the number of SNP markers needed to perform whole genome scans is divided by at least ten LUPA is a European effort gathering experts in genomics to take advantage of this extraordinary genetic model Veterinary clinics from 12 European countries will collect DNA samples from large cohorts of dogs suffering from a range of thoroughly defined diseases of relevance to human health The diseases are described under the different workpackage WP1 to WP5 within the left column Once the different cohorts will be built DNA samples will be sent to a centralized high throughput SNP genotyping facility The SNP genotypes will be stored in central database and made available to participating collaborating centres who will analyze the data with the support of dedicated statistical genetics platforms Following genome wide association and fine mapping the candidate genes will be followed up at the molecular level by expert animal and human genomics centers This innovative approach using the dog model will ultimately provide insights into the pathogenesis of common human diseases its primary goal

    Original URL path: http://www.cng.fr/fr/projects/fp7_lupa.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    PCRD5 EID DNA tracing EPIGENOME EUMORPHIA EURAGEDIC EURNETGEN EUROAS GENOMIC BANK INFRAQTL MADO Autres programmes franco japonaise franco croate PHENOGENE READNA REvolutionary Approaches and Devices for Nucleic Acid Analysis Coordinator Contact Person MAY Elizabeth Ms Tel 33 1 60878404 Fax 33 1 60878484 Email Contact Organisation COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES RUE LEBLANC Batiment le Ponant D PARIS 15 FRANCE Web site https www cng fr READNA Project description The READNA consortium includes projects to accelerate new breakthrough DNA sequencing technologies and methods to enhance existing analysis methods The consortium includes 16 European partners from both academia and industry and launches with a 12m grant via the European Commission s seventh Framework Programme FP7 Participants come from a diverse range of scientific disciplines The interdisciplinary nature of the consortium will allow the exploration of novel concepts of nucleic acid analysis Via the READNA project results are expected to improve many aspects of patient care including the development of new personalised medical strategies and treatments The ultimate aim will be to progress technologies enabling sequencing of an entire human genome for 1000 in less than one day Participants OXFORD NANOPORE TECHNOLOGIES LTD UNITED KINGDOM LIFE TECHNOLOGIES GMBH

    Original URL path: http://www.cng.fr/fr/projects/fp7_readna.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    franco croate PHENOGENE SYBARIS Finding biomarkers of anti microbial drug resistance via a systems biology analysis of fungal pathogen interactions with the human immune system Coordinator Contact Person Tom RATCLIFFE Mr Tel 44 1223492520 Fax 44 1223494468 Email Contact Organisation EUROPEAN MOLECULAR BIOLOGY LABORATORY Meyerhofstrasse HEIDELBERG DEUTSCHLAND Web site http www embl org Objective We propose a systems biology study of the specificity of response of the cell mediated immune system to fungal microorganisms in order to investigate the genetic basis of susceptibility to fungal disease and elucidate molecular mechanisms of drug resistance in fungal pathogens An integrative approach combining high throughput and traditional wet lab work with computational and bioinformatics methods will be applied to identify biomarkers of resistance to currently available treatments and to develop novel putative drug target genes and pathways in different fungi We will use Saccharomyces cerevisiae a normally non pathogenic yeast model organism Candida albicans and Aspergillus fumigatus two major recognized fungal pathogens as well as other Aspergillus spp known to be multi drug resistant and difficult to treat This project meets the criteria of the call the strategic objective of which is to confront the increasing emergence and spread of antimicrobial drug resistant pathogens in Europe by addressing a well defined class of infectious disease caused by fungal pathogens with significant morbidity and mortality in a large segment of the population and a high economic cost due to resistance The anticipated results are highly relevant to society in terms of reducing the burden of mortality and suffering in immunosuppressed patients and in terms of reducing medical costs associated with treating opportunistic fungal infections The potential economic upside for novel broad spectrum anti infectives is very large The worldwide market for antifungals is currently estimated at 4 billion US annually We tackle the issues

    Original URL path: http://www.cng.fr/fr/projects/fp7_sybaris.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    Timothy J Professor Tel 44 02083834253 Fax 44 02083838577 Email Contact Organisation MEDICAL RESEARCH COUNCIL MRC CLINICAL SCIENCES CENTRE CSC 20 Park Cresent LONDON UNITED KINGDOM Project description Determining the molecular basis of natural phenotypic variation including inter individual susceptibility to common diseases is a central challenge of post genome genetics The rat is a leading model species for research in physiology pharmacology and toxicology and for the study of a wide range of common genetically complex human diseases Decades of exquisite phenotyping and detailed analyses in rat experimental crosses have led to localization of hundreds of quantitative trait loci QTLs containing genes that confer susceptibility to complex disease phenotypes However in common with studies in other organisms few genes underlying these genetically complex traits have as yet been identified The availability of the rat genome sequence and genome scale technologies along with the ability to clone fertile adult rats has substantially advanced the potential for functional genomics research in the rat model The European Rat Tools for Functional Genomics EURATools consortium draws together leading European researchers in rat genetics pharmacology toxicology disease pathophysiology and genome biology and informatics The central aim of this project is the development of integrated genome tools that will generate knowledge which can be translated into improvements in healthcare for highly prevalent diseases in the European Union The EURATools aims will be achieved by integrating high throughput sequencing and genotyping with informatics by intensive analysis of phenotypes gene sequence and gene expression in congenic strains to identify genes and regulatory pathways for a wide range of rat disease phenotypes and by establishment of optimised protocols for rat gene targeting These new resources will significantly improve our understanding of complex genetic traits and will enhance prospects for drug development and strategies for preventing and treating some

    Original URL path: http://www.cng.fr/fr/projects/fp6_euratools.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    about the development and function of the inner ear to identify the molecular defects underlying hereditary hearing impairments HI including presbycusis one of the most frequent forms of HI Achieving these objectives will facilitate the development of therapies for alleviating HI In order to address the above issues the EuroHear project is organised into 4 components The identification of genes underlying sensorineural HI in humans and mice The analysis of the molecular and cellular mechanisms underlying the development and function of The hair bundle The ribbon synapses of the hair cell and outer hair cell electromotility The ion channels ion transporters and gap junction channels that contribute to the potassium homeostasis The standardisation implementation and development of technologies The development of new tools for preventing and curing HI Currently we identify a multidisciplinary approach as the sina qua non condition for further progress in understanding the inner ear The EuroHear consortium comprises a group of laboratories that are world experts in a variety of hearing research fields EuroHear is a continuation and extension of a previous European consortium that has successively tackled early onset Mendelian forms of deafness and hearing loss The success of this European consortium which has identified half of the 37 known genes for isolated forms of HI in humans has been due in large part to intense collaboration between human and mouse geneticists Expected contributions of EuroHear include a standardisation of investigative protocols the provision of access to large scale platforms for genetics and genomic analysis the development and diffusion of physiological and biophysical techniques of relevance for functional investigations of the inner ear the creation of a variety of mouse Participants PHILIPPS UNIVERSITET MARBURG GERMANY UNIVERSITÄTSMEDIZIN GÖTTINGEN GEORG AUGUST UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS GERMANY INSERM TRANSFERT SA FRANCE MAX DELBRÜCK CENTRUM FÜR MOLEKULARE MEDIZIN

    Original URL path: http://www.cng.fr/fr/projects/fp6_eurohear.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    THE UNIVERSITY OF OXFORD WELLCOME TRUST CENTRE FOR HUMAN GENETICS University Offices Wellington Square OXFORD UNITED KINGDOM Project description The theme of this proposal is to develop methodologies that integrate functional genomic tools and genetic strategies to address major unresolved questions concerning the molecular basis of common diseases using coronary artery disease CAD as an example Progress in functional genomics technologies have dramatically increased the density of gene expression datasets providing information on the expression of individual genes and gene networks at the levels of transcription translation protein abundance and activity and metabolic processes They will impact prevalent human complex disorders by providing new information for disease prevention and treatment Risk factors of CAD represent dominant causes of premature death and disability Owing to the complexity of CAD our understanding of the pathophysiological processes involved is limited In this programme implemented by international investigators and SMEs we shall use functional genomics technologies metabonomics proteomics and transcriptomics to generate a comprehensive and multidimensional description of well defined states of CAD in selected clinical cohorts and animal models which will be used as a platform for studying the causes of CAD We will initially test the power of high density functional genomic

    Original URL path: http://www.cng.fr/fr/projects/fp6_fgentcard.html (2016-01-29)
    Open archived version from archive



  •